ImmunityBio, Inc. IBRX

$IBRX Oh, just got another month lysalary today. Double pay!!!

$IBRX Own 24K shares. I'll post my profits herer everyday and not going to sell a single share until I get 1000% profits. May add more shares at every dip.

$IBRX Own 24K shares. Not going to sell a single share. Will hold for a least 3 years to take 1000% profits and retire.

$IBRX shorts are so exciting when the stock drup 4% after a 70% pump. What a joke hahaha. I'll keep buying every dip, already 24K shares.

$IBRX thoracic surgeon, urologist, oncologist are going to buy the stock after they hear Anktiba in the conference. We have to buy it before these rich guys pump the price!!!!

$IBRX 24K shares at average 4.9. Why wound you sell a company that able to earn 2.5B annually with market cap only 5b? Buy and hold. Take it long.See you at SP 40 3 years later.

$IBRX Shorts are trying to escape haha. Not going to sell any of my shares.

$IBRX burn the shorts, own 24K shares, not going to sell a single share .

$IBRX 24K avg.4.97 Not going to take profit until 50 per share. Hold long until we get LUNG indication.

$IBRX Bought 22,000 shares of IBRX on 4/25 at an average price of $4.97. Plan to hold for 3-5 years aiming for a 500% profit and retirement. (1)Anktiva avoid 90% of cystectomy in bladder cancer and has applied for inclusion in the NCCN guidelines (2)Received FDA approval on 4/22/24 and will be available for sale on 5/6/24 (3)Expected to treat 20,000 patients annually (4)Treatment regimen consists of 36 doses over 37 months, priced at $35,800 per dose (5)Estimated annual revenue potential of $8.5 billion for bladder cancer treatment in the US, with current market cap at only $5 billion (6)Rapid FDA submissions have been made in Canada, the UK, Germany, France, Spain, and Italy. Potential strategic partners are approaching IBRX (7)Phase 3 clinical trial underway for BCG-naive bladder cancer patients (8)Lung cancer clinical trial has shown a doubling of survival time from 7-8 months to 14-18 months (9)Lung cancer trial data submitted for publication, while bladder cancer trial results have been published in the prestigious NEJM (10)Clinical trials ongoing for lung cancer, colon cancer, ovarian cancer, Lynch syndrome, and HIV. (11)Attending the AUA conference from May 3-6, 2024, and the ASCO conference from May 31 to June 4, 2024. Scheduled meeting with FDA in June to discuss lung indication application (12)Earnings call scheduled for July!!!